Malignant hypertension: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 36: Line 36:


==Treatment==
==Treatment==
The most commonly used intravenous drug is [[nitroprusside]]. An alternative for patients with renal insufficiency is intravenous [[fenoldopam]]. A commonly used drug is IV [[fenoldopam]]. [[Labetalol]] is another common alternative, providing easy transition from IV to oral (PO) dosing. Beta-blockade can be accomplished intravenously with [[esmolol]] or [[metoprolol]]. [[Hydralazine]] is reserved for use in pregnant patients, while [[phentolamine]] is the drug of choice for a [[pheochromocytoma]] crisis. iv sodium nitroprusside should never be used as it can cause a rapid uncontrollable drop in blood pressure.
The most commonly used intravenous drug is [[nitroprusside]]. An alternative for patients with renal insufficiency is intravenous [[fenoldopam]]. [[Labetalol]] is another common alternative, providing easy transition from IV to oral (PO) dosing. Beta-blockade can be accomplished intravenously with [[esmolol]] or [[metoprolol]]. [[Hydralazine]] is reserved for use in pregnant patients, while [[phentolamine]] is the drug of choice for a [[pheochromocytoma]] crisis. iv sodium nitroprusside should be used with caution as it can cause a rapid uncontrollable drop in blood pressure.


==Prognosis==
==Prognosis==

Revision as of 15:29, 22 October 2011

Malignant hypertension
ICD-10 I10
ICD-9 401.0[1]
DiseasesDB 7788
MeSH D006974

WikiDoc Resources for Malignant hypertension

Articles

Most recent articles on Malignant hypertension

Most cited articles on Malignant hypertension

Review articles on Malignant hypertension

Articles on Malignant hypertension in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Malignant hypertension

Images of Malignant hypertension

Photos of Malignant hypertension

Podcasts & MP3s on Malignant hypertension

Videos on Malignant hypertension

Evidence Based Medicine

Cochrane Collaboration on Malignant hypertension

Bandolier on Malignant hypertension

TRIP on Malignant hypertension

Clinical Trials

Ongoing Trials on Malignant hypertension at Clinical Trials.gov

Trial results on Malignant hypertension

Clinical Trials on Malignant hypertension at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Malignant hypertension

NICE Guidance on Malignant hypertension

NHS PRODIGY Guidance

FDA on Malignant hypertension

CDC on Malignant hypertension

Books

Books on Malignant hypertension

News

Malignant hypertension in the news

Be alerted to news on Malignant hypertension

News trends on Malignant hypertension

Commentary

Blogs on Malignant hypertension

Definitions

Definitions of Malignant hypertension

Patient Resources / Community

Patient resources on Malignant hypertension

Discussion groups on Malignant hypertension

Patient Handouts on Malignant hypertension

Directions to Hospitals Treating Malignant hypertension

Risk calculators and risk factors for Malignant hypertension

Healthcare Provider Resources

Symptoms of Malignant hypertension

Causes & Risk Factors for Malignant hypertension

Diagnostic studies for Malignant hypertension

Treatment of Malignant hypertension

Continuing Medical Education (CME)

CME Programs on Malignant hypertension

International

Malignant hypertension en Espanol

Malignant hypertension en Francais

Business

Malignant hypertension in the Marketplace

Patents on Malignant hypertension

Experimental / Informatics

List of terms related to Malignant hypertension

Cardiology Network

Discuss Malignant hypertension further in the WikiDoc Cardiology Network
Adult Congenital
Biomarkers
Cardiac Rehabilitation
Congestive Heart Failure
CT Angiography
Echocardiography
Electrophysiology
Cardiology General
Genetics
Health Economics
Hypertension
Interventional Cardiology
MRI
Nuclear Cardiology
Peripheral Arterial Disease
Prevention
Public Policy
Pulmonary Embolism
Stable Angina
Valvular Heart Disease
Vascular Medicine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Malignant hypertension is a complication of hypertension characterized by very elevated blood pressure, and organ damage in the eyes, brain, lung and/or kidneys. It differs from other complications of hypertension in that it is accompanied by papilledema. Systolic and diastolic blood pressures are usually greater than 200 and 140, respectively.

History

The most common presentations of hypertensive emergencies at an emergency department are chest pain (27%), dyspnea (22%), and neurologic deficit (21%). The primary cardiac symptoms are angina, myocardial infarction, and pulmonary edema. Orthostatic symptoms may be prominent. Neurologic presentations are occipital headache, cerebral infarction or hemorrhage, visual disturbance, or hypertensive encephalopathy (a symptom complex of severe hypertension, headache, vomiting, visual disturbance, mental status changes, seizure, and retinopathy with papilledema). Medications or drugs that may cause a hypertensive emergency include cocaine, monoamine oxidase inhibitors (MAOIs), and oral contraceptives; the withdrawal of beta-blockers, alpha-stimulants (such as clonidine), or alcohol, steroids also may cause hypertensive emergency. Renal disease may present as oliguria (renal failure) or any of the typical features of renal failure. Gastrointestinal symptoms are nausea and vomiting.

Physical

Cardiovascular system

Blood pressure must be checked in both arms to screen for aortic dissection or coarctation. If coarctation is suspected, blood pressure also should be measured in the legs. Screen for carotid or renal bruits. Listen for a third or fourth heart sound or murmurs. Volume status should be assessed, with orthostatic vital signs, examination of jugular veins, assessment of liver size, and investigation for peripheral edema and pulmonary rales.

Central nervous system

A complete neurologic examination is needed to screen for localizing signs. Focal neurologic signs might not be attributable to encephalopathy. Focal signs mandate screening for subarachnoid hemorrhage, infarct, or the presence of a mass. A funduscopic examination may reveal silver wiring (Grade I retinopathy), AV nipping (Grade II) flame-shaped retinal hemorrhages, soft exudates (Grade III), or papilledema (Grade IV).

Lab studies

Lab studies include a complete blood count and electrolytes, coagulation profile, and urinalysis, cardiac enzymes, urinary catecholamines, thyroid-stimulating hormone (TSH), and 24-hour urine collection for vanillylmandelic acid (VMA) and catecholamines.

Renal function should be evaluated through a urinalysis, complete chemistry profile, and complete blood count. Expected findings include elevated BUN and creatinine, hyperphosphatemia, hyperkalemia or hypokalemia, glucose abnormalities, acidosis, hypernatremia, and evidence of microangiopathic hemolytic anemia. Urinalysis may reveal proteinuria, microscopic hematuria, and RBC or hyaline casts. In patients with hyperaldosteronism (a secondary cause of hypertension), aldosterone promotes renal potassium wasting, resulting in low serum potassium.

The chest radiograph is useful for assessment of cardiac enlargement, pulmonary edema, or involvement of other thoracic structures, such as rib notching with aortic coarctation or a widened mediastinum with aortic dissection. Other tests, such as head CT scan, transesophageal echocardiogram, and renal angiography, are indicated only as directed by the initial workup. The ECG is necessary to screen for ischemia, infarct, or evidence of electrolyte abnormalities or drug overdose.

Treatment

The most commonly used intravenous drug is nitroprusside. An alternative for patients with renal insufficiency is intravenous fenoldopam. Labetalol is another common alternative, providing easy transition from IV to oral (PO) dosing. Beta-blockade can be accomplished intravenously with esmolol or metoprolol. Hydralazine is reserved for use in pregnant patients, while phentolamine is the drug of choice for a pheochromocytoma crisis. iv sodium nitroprusside should be used with caution as it can cause a rapid uncontrollable drop in blood pressure.

Prognosis

Prior to effective therapy, life expectancy was less than 2 years, with most deaths resulting from stroke, renal failure, or heart failure. The survival rate at 1 year was less than 25% and at 5 years was less than 1%. With current therapy, including dialysis, the survival rate at 1 year is greater than 90% and at 5 years is 80%. The most common cause of death is cardiac, with stroke and renal failure also common. The single greatest prognostic factor in malignant hypertension is renal function, with renal insufficiency secondary to malignant nephrosclerosis being strongly associated with poorer outcomes.

References

See also


Template:WikiDoc Sources